Elkfork Partners LLC bought a new position in shares of Eli Lilly and Co (NYSE:LLY) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 42,336 shares of the company’s stock, valued at approximately $3,576,000.
Other large investors also recently modified their holdings of the company. Gradient Investments LLC bought a new position in shares of Eli Lilly and during the fourth quarter worth $103,000. Avestar Capital LLC bought a new position in shares of Eli Lilly and during the fourth quarter worth $100,000. MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and during the second quarter worth $128,000. Willingdon Wealth Management bought a new position in shares of Eli Lilly and during the third quarter worth $138,000. Finally, Front Row Advisors LLC bought a new position in shares of Eli Lilly and during the fourth quarter worth $137,000. Hedge funds and other institutional investors own 77.62% of the company’s stock.
In other news, SVP Jeffrey N. Simmons sold 9,625 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the sale, the senior vice president now owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Donald A. Zakrowski sold 860 shares of the stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $76.50, for a total transaction of $65,790.00. The disclosure for this sale can be found here. In the last three months, insiders sold 15,261 shares of company stock worth $1,225,085. Insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and stock opened at $74.76 on Friday. Eli Lilly and Co has a 12 month low of $73.69 and a 12 month high of $89.09. The firm has a market cap of $83,846.11, a price-to-earnings ratio of -373.78, a PEG ratio of 1.39 and a beta of 0.28. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. During the same quarter in the prior year, the firm posted $0.95 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. sell-side analysts expect that Eli Lilly and Co will post 4.87 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Elkfork Partners LLC Invests $3.58 Million in Eli Lilly and Co (LLY)” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3298508/elkfork-partners-llc-invests-3-58-million-in-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.